Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | HTR3A | P46098 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386039 | 1.00 | HTR4 (1.00) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22532550 | 0.99 | HTR4 (0.98) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL548053 | 0.93 | HTR4 (1.00) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL29767008 | 0.93 | HTR4 (1.00) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6836668 | 0.92 | HTR4 (1.00) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27977233 | 0.91 | HTR4 (0.96) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL9117893 | 0.88 | HTR4 (0.78) | HTR4CYP3A4GLA | |
| SCHEMBL9118349 | 0.88 | HTR4 (0.78) | HTR4CYP3A4GLA | |
| SCHEMBL9118322 | 0.86 | HTR4 (0.76) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL9116887 | 0.86 | HTR4 (0.76) | HTR4CYP3A4GLAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-1995025100-A1 | USE OF 4-AMINO-5-CHLORO-2-METHOXYBENZOIC ESTERS AS 5-HT4 AGONISTS | SANOFI (FR) | 1995-09-21 | — | — | WO | claimed |
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| EP-2563404-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2016-09-21 | — | — | EP | disclosed |
| US-9168250-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2015-10-27 | — | — | US | disclosed |
| EP-2903987-A1 | PHOSPHOLIPID DRUG ANALOGS | Telormedix SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-8859537-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2014-10-14 | — | — | US | disclosed |
| WO-2014053222-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2014-04-10 | — | — | WO | disclosed |
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | UNIVERSITÉ DE NÎMES (FR) | 2013-10-17 | — | — | US | disclosed |
| US-8436021-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2013-05-07 | — | — | US | disclosed |
| US-6506580-B1 | Gastrointestinal, nervous system and cardiovascular disorders; Alzheimer*s and Parkinson*s disease; antiarrhythmia agents, cognition activators | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20020173505-A1 | Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders | SKOGVALL STAFFAN (SE) | 2002-11-21 | — | — | US | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | disclosed |
| EP-1173168-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | Respiratorius AB (SE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | disclosed |
| WO-1995025100-A1 | USE OF 4-AMINO-5-CHLORO-2-METHOXYBENZOIC ESTERS AS 5-HT4 AGONISTS | SANOFI (FR) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173505-A1 | Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders | HTR4, HTR2C, HTR5A | HTR4 1/4885CYP3A4 762/4885GLA 3525/4885 |
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | OPRL1, HTR4, OPRM1 | HTR4 2/4885CYP3A4 3007/4885GLA 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.